In a critical move to curb the escalating threat of the Bundibugyo ebolavirus (BDBV) in the Democratic Republic of the Congo (DRC) and Uganda, the Coalition for Epidemic Preparedness Innovations (CEPI) has officially announced the fast-tracking of three novel vaccine candidates. As the BDBV strain continues to circulate with no licensed vaccines or established clinical development pipelines to counter it, this multinational initiative represents one of the most significant public health interventions in the region in recent years.
The candidates, developed by IAVI, Moderna, and the University of Oxford, were selected following a rigorous global review process conducted in close coordination with the World Health Organization (WHO), the Africa Centres for Disease Control and Prevention (Africa CDC), and various other international health stakeholders. By fast-tracking these platforms, CEPI aims to shorten the timeframe between research and deployment, providing a potential shield for vulnerable populations currently at risk of infection.
The Urgency of a Forgotten Threat
The Bundibugyo ebolavirus is a member of the Ebolavirus genus, notorious for causing severe hemorrhagic fever with high case-fatality rates. Despite the periodic danger it poses, BDBV has historically been overshadowed by the Zaire ebolavirus, which caused the massive West African epidemic of 2014–2016. Because BDBV has only been identified in two prior outbreaks, it has not previously received the commercial or pharmaceutical attention required to bring a vaccine to market.
"With the Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," said Richard Hatchett, CEO of CEPI. "CEPI’s urgent funding and support for these three promising candidates aims to advance safe, effective vaccines to help control this epidemic and prevent further loss of life."
Chronology of Development and Strategic Selection
The selection of these three specific platforms is not coincidental; it is a strategic utilization of proven vaccine architectures.
IAVI’s rVSV Approach
IAVI’s candidate, which traces its origins to research at The University of Texas Medical Branch, employs a recombinant vesicular stomatitis virus (rVSV) vector. This technology is already well-validated, as it serves as the backbone for the only currently licensed Zaire ebolavirus vaccine. Its deployment during the 2025 Sudan virus outbreak in Uganda provided further real-world evidence of its utility in rapid-response scenarios.
CEPI has committed $3.2 million to this candidate to facilitate the generation of a Master Virus Seed stock and the transfer of production processes to a contract development and manufacturing organization (CDMO) for Good Manufacturing Practice (GMP) production. While the vaccine has demonstrated efficacy in non-human primate models, it remains in the pre-clinical stage for human application. The WHO has identified this candidate as the most immediate priority due to the maturity of the underlying platform.
Moderna’s mRNA Innovation
Moderna’s involvement marks a significant expansion of mRNA technology beyond the scope of SARS-CoV-2. CEPI is investing up to $50 million in this program, a substantial commitment intended to fund preclinical testing, Phase 1 clinical trials, and concurrent manufacturing. This "at-risk" manufacturing strategy is designed to allow the program to pivot immediately to Phase 2 and 3 trials should initial safety data prove positive.
The University of Oxford’s ChAdOx1 Platform
The University of Oxford is utilizing its ChAdOx1 viral vector platform, the same technology that powered the AstraZeneca COVID-19 vaccine. With an investment of $8.6 million from CEPI, the university is moving to initiate preclinical testing and the production of clinical-grade doses. The platform has shown cross-protective potential against other filoviruses, including the Sudan and Marburg viruses, making it a versatile candidate for future outbreak preparedness.
Supporting Data and Financial Context
The financial architecture behind this initiative highlights the disparity between public health needs and commercial viability. For many pharmaceutical entities, developing vaccines for rare or localized outbreaks is considered a "commercially risky" endeavor.
Moderna, for instance, has faced a complex financial landscape over the past year. With fourth-quarter 2025 revenue down 30% year-over-year and first-quarter 2026 earnings totaling $0.4 billion, the company is recalibrating its focus. In 2025 alone, Moderna spent $3.1 billion on research and development while reporting $1.9 billion in revenue. By offloading the costs of the BDBV program to CEPI, Moderna is able to continue advancing its mRNA filovirus pipeline—gaining invaluable clinical data and refining its manufacturing processes—without further impacting its bottom line.
This public-private partnership comes at a turbulent time for federal research policy in the United States. In August 2025, the Trump administration terminated 22 government contracts specifically focused on mRNA vaccine development, citing a desire to wind down federal investment in the platform. Consequently, CEPI’s $50 million injection into Moderna’s mRNA research acts as a critical lifeline for a technology that many experts argue is essential for future pandemic preparedness.
Official Responses and Stakeholder Engagement
The collaborative nature of this initiative is designed to ensure that the vaccines reach the people who need them most, rather than languishing in the labs of developed nations.
Stephane Bancel, CEO of Moderna, emphasized the commitment to global health equity, stating, "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
However, the responsibility for these vaccines does not end at the research phase. CEPI is currently engaged in high-level coordination with Gavi, the Vaccine Alliance, the World Bank, and various development finance institutions. The goal is to establish "surge financing" mechanisms, ensuring that if any of the three candidates prove successful in Phase 3 trials, there will be no bottleneck in procurement or distribution.
Long-term Implications for Global Health Security
The fast-tracking of these BDBV vaccines signals a shift in how the international community approaches "orphan" diseases—illnesses that are deadly but lack the global market incentive to justify standard corporate investment.
1. Diversification of Platforms
By simultaneously testing three different platforms—rVSV, mRNA, and ChAdOx1—CEPI is hedging its bets. If one technology fails to elicit the desired immune response or presents safety hurdles in the field, the others provide a robust backup. This "portfolio" approach is a departure from the single-track development models that historically delayed vaccine deployment in developing nations.
2. The Role of mRNA Beyond COVID-19
The infusion of capital into Moderna’s mRNA program is a litmus test for the technology’s durability. If the BDBV vaccine proves effective, it will solidify mRNA as a modular platform capable of being "programmed" to target diverse pathogens, from Ebola to emerging zoonotic viruses. This could fundamentally alter the economics of vaccine development, potentially making the process faster and more adaptable.
3. Strengthening Regional Capacity
A key, though often overlooked, aspect of the CEPI initiative is its focus on the DRC and Uganda. By focusing on the clinical data needs of these specific regions, the project encourages the integration of local healthcare systems into the trial process. This ensures that the vaccines are not only safe but also logistically viable for the cold-chain and infrastructure limitations often found in sub-Saharan Africa.
4. Policy Tensions and Future Funding
The recent U.S. government withdrawal from mRNA funding has created a vacuum that organizations like CEPI are increasingly forced to fill. This raises a broader geopolitical question: if national governments retreat from funding innovative vaccine research, can international coalitions successfully sustain the global health infrastructure? The success of these BDBV vaccine candidates will likely be used as a primary case study in future discussions regarding the necessity of a permanent, well-funded, global mechanism for epidemic defense.
Conclusion: A Path Forward
As the BDBV outbreak in the DRC and Uganda continues to pose a significant threat to regional stability and public health, the initiatives led by CEPI represent a vital effort to translate scientific innovation into humanitarian action. By leveraging the expertise of IAVI, Moderna, and the University of Oxford, the global health community is taking a proactive stance against a virus that has for too long been ignored by the commercial market.
While the path to a licensed vaccine remains fraught with technical and clinical challenges, the integration of funding, research, and diplomatic coordination provides a blueprint for how the world might better handle future outbreaks. Whether these vaccines can be delivered in time to halt the current epidemic remains to be seen, but the commitment to action marks a significant milestone in the ongoing struggle to protect the world’s most vulnerable populations from emerging infectious diseases.
CEPI continues to keep its doors open to additional partners and candidates through its ongoing open call for proposals, ensuring that the hunt for effective countermeasures remains as dynamic and relentless as the pathogens themselves.
About the Author
